Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan

To read the full story

• Sign In
• Subscribe

Related Article

• Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
  October 28, 2025

• Shionogi Nets Record Earnings for 3rd Consecutive Year on Overseas Expansion
  May 13, 2025

• Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
  October 29, 2024

• Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
  May 14, 2024

• Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
  November 1, 2023

• Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
  August 1, 2023

• Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
  May 11, 2023

• Shionogi Hits Record High Earnings on Xocova Boon in FY2022
  May 11, 2023

• Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
  January 31, 2023

• Japan Govt to Purchase Another 1 Million Courses of Xocova
  December 14, 2022

• Japan Should Hone Emergency Approval Scheme Based on Xocova Example
  November 28, 2022

• Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
  November 25, 2022

• Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
  November 24, 2022

• Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
  November 15, 2022

• Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
  November 1, 2022

• Shionogi’s COVID Pill Hits Main Goal in PIII, Discussion on Regulatory Path to Follow
  September 29, 2022

• Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
  August 2, 2022

• Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
  July 21, 2022

• Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
  June 23, 2022